|
[1]
|
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209 − 49. https://doi.org/10.3322/caac.21660CrossRef
|
|
[2]
|
Xia CF, Dong XS, Li H, Cao MM, Sun DQ, He SY, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl) 2022;135(5):584 − 90. https://doi.org/10.1097/CM9.0000000000002108CrossRef
|
|
[3]
|
World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. 2020. https://www.who.int/publications/i/item/9789240014107. [2022-6-28]. |
|
[4]
|
National Health Commission of the People’s Republic of China. Action plan to accelerate the elimination of cervical cancer. http://www.nhc.gov.cn/fys/s3581/202301/42c2c95b6db84f9cb356cfdf1edbbac7.shtml. [2023-1-5]. (In Chinese). |
|
[5]
|
Bruni L, Saura-Lázaro A, Montoliu A, Brotons M, Alemany L, Diallo MS, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019. Prev Med 2021;144:106399. https://doi.org/10.1016/j.ypmed.2020.106399CrossRef
|
|
[6]
|
Drolet M, Bénard É, Pérez N, Brisson M, HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet 2019;394(10197):497 − 509. https://doi.org/10.1016/S0140-6736(19)30298-3CrossRef
|
|
[7]
|
Falcaro M, Castañon A, Ndlela B, Checchi M, Soldan K, Lopez-Bernal J, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet 2021;398(10316):2084 − 92. https://doi.org/10.1016/S0140-6736(21)02178-4CrossRef
|
|
[8]
|
Kjaer SK, Dehlendorff C, Belmonte F, Baandrup L. Real-world effectiveness of human papillomavirus vaccination against cervical cancer. J Natl Cancer Inst 2021;113(10):1329 − 35. https://doi.org/10.1093/jnci/djab080CrossRef
|
|
[9]
|
WHO. Human papillomavirus vaccines: WHO position paper, May 2017. Wkly Epidemiol Rec 2017;92(19):241-68. https://pubmed.ncbi.nlm.nih.gov/28530369/. |
|
[10]
|
World Health Organization. Human papillomavirus vaccines: WHO position paper, December 2022. Wkly Epidemiol Rec 2022;97:645-72. https://www.who.int/publications/i/item/who-wer9750-645-672. |
|
[11]
|
National Health Commission of the People’s Republic of China. Interpretation of the document action plan to accelerated elimination of cervical cancer (2023-2030). http://www.nhc.gov.cn/fys/s3582/202301/04b918b28fb0418b9ca00dabcd29e1dc.shtml. [2023-1-20]. (In Chinese). |
|
[12]
|
Luciani S, Bruni L, Agurto I, Ruiz-Matus C. HPV vaccine implementation and monitoring in Latin America. Salud Publica Mex 2018;60(6):683 − 92. https://doi.org/10.21149/9090CrossRef
|